IPI 549

Drug Profile

IPI 549

Alternative Names: IPI549

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intellikine
  • Developer Infinity Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase gamma inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 26 Sep 2017 Bristol-Myers Squibb expand clinical collaboration designed to evaluate IPI 549 in combination with nivolumab for Cancer
  • 27 Jul 2017 Takeda and Infinity Pharmaceuticals amend licensing agreement for IPI 549
  • 01 Apr 2017 Interim adverse events and pharmacokinetics data from a phase I/Ia trial presented at the American Association for Cancer Research Annual Meeting 2017 (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top